ortx-6k_20190701.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2019

Commission File Number: 001-38722

 

ORCHARD THERAPEUTICS PLC

(Translation of registrant’s name into English)

 

108 Cannon Street

London EC4N 6EU

United Kingdom

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F     Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

 

 

 

 



Results of Annual General Meeting

 

On June 26, 2019, Orchard Therapeutics plc (the “Company”) held its 2019 Annual General Meeting (the “Annual General Meeting”). At the Annual General Meeting, all the resolutions set out in the Notice of Annual General Meeting sent to shareholders on May 31, 2019 were duly proposed and approved by a show of hands.  

 

The matters presented for a vote and the related results are as follows:

 

 

Ordinary Resolutions

For

Against

Withheld

1.

To receive, consider and adopt the Directors’ and Auditors’ Reports and Statement of Accounts for the year ended 31 December 2018 and note that the Directors do not recommend payment of a dividend

36,974,057

580

250

2.

To approve the Directors’ Remuneration Report

36,304,691

669,446

750

3.

To approve our Directors’ Remuneration Policy

33,863,941

3,110,196

750

4.

To elect Hubert Gaspar as a Director

36,909,927

64,710

250

5.

To elect Alicia Secor as a Director

35,123,504

1,850,893

490

6.

To re-appoint PricewaterhouseCoopers LLP as Auditor

36,969,310

5,327

250

7.

To authorise the Directors to determine the Auditor’s remuneration

36,935,127

39,510

250

 

Special Resolutions

 

 

 

8.

To authorise the Directors to allot shares pursuant to Section 551 of the Companies Act 2006 (the “Act”)

32,407,543

4,566,194

1,150

9.

Subject to the passing of Resolution 8, to authorise the Directors to allot equity securities, under Section 570 of the Act as if Section 561(1) of the 2006 Act did not apply to such allotment 

32,407,323

4,566,414

1,150

 

The full text of each resolution passed at the Annual General Meeting is set out in the Notice of Annual General Meeting sent to shareholders on May 31, 2019 and furnished as an exhibit to a Form 6-K filed with the U.S. Securities and Exchange Commission on June 3, 2019.

 

Other Events

 

On June 25, 2019, Hong Fang “Simone” Song, a Class I Director of the Company, stepped down from the Company’s Board of Directors effective immediately prior to the Annual General Meeting on June 26, 2019 and at the completion of her term.  Ms. Song’s decision to resign was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

 

 

 

 

 

 

 

 

 

ORCHARD THERAPEUTICS PLC

 

 

 

 

Date: July 1, 2019

 

 

 

By:

 

/s/ Frank E. Thomas

 

 

 

 

 

 

Frank E. Thomas

Chief Financial Officer